LANNETT COMPANY

 LCIのチャート


 LCIの企業情報

symbol LCI
会社名 Lannett Co. Inc. (LANNETT COMPANY)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 ラネット・カンパニー(Lannett Company Inc.)はジェネリック医薬品(後発医薬品)を開発、製造、販売、販売する。同社は、子会社Silarx Pharmaceuticals、Inc.によって製造された小売店頭商品の小規模ポートフォリオを除き、処方薬品を製造および/あるいは販売を行う。2016年6月30日現在、同社の製品には、アセタゾラミド錠、ブタルビタール、アセトアミノフェンおよびカフェイン錠、アスピリンおよびカフェインカプセル、C-局所溶液、ジゴキシン錠、Glycolax Rx、一硝酸イソソルビドCR、レボチロキシンNa錠、メチルフェニデートHCL CD、メチルフェニデートER、ニフェジピンCR、オメプラゾールDR、オキシブチニンER、ピロカルピンHCl錠、パントプラゾールDR、トリアムテレンw/ヒドロクロロチアジドカプセルおよびウルソジオールカプセルが含まれる。同社が開発中の製品は経口固体製品(錠剤/カプセル)、経口溶液、鼻用医薬、局所適用および注射用製品などを含む。  ラネットは米国の医薬品メ―カ―。ブランド医薬品のジェネリック版の開発、製造、販売。固体経口、徐放性、局所、経鼻および経口の仕上げ溶剤を提供。 主要製品は、甲状腺疾患用のレボチロキシンナトリウム、うっ血性心不全のためのジゴキシン、片頭痛のためにブタルビタ―ルを含む製品、麻酔薬「コカイン・トピカル」、鎮痛剤としての硫酸モルヒネ経口溶剤など。  
本社所在地 9000 State Road Philadelphia PA 19136 USA
代表者氏名 Patrick G. LePore
代表者役職名 Independent Chairman of the Board
電話番号 +1 215-333-9000
設立年月日 15311
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 1251人
url www.lannett.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 209.88800
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 318.22260
売上高 (百万ドル) 694.06900
企業価値(EV) (百万ドル) 967.90060
当期純利益 (百万ドル) -280.15500
決算概要 BRIEF: For the six months ended 31 December 2018 Lannett Company Inc. revenues increased 3% to $348.8M. Net loss before extraordinary items totaled $275.2M vs. income of $43.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Asset impairment charges increase from $0K to $369.5M (expense) Other decrease from $3.1M (income) to $1M (expense).

 LCIのテクニカル分析


 LCIのニュース

   Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026  2021/04/06 11:21:00 Benzinga
PHILADELPHIA , April 6, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI ) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior secured notes due 2026 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act. The Notes are expected to bear interest that will be payable semiannually. The Notes will mature in April 2026 , unless earlier redeemed or repurchased in accordance with their terms. … Full story available on Benzinga.com
   Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets  2021/02/08 11:52:00 PR Newswire
PHILADELPHIA, Feb. 8, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received approval from the U.S. Food and Drug Administration…
   Lannett (NYSE:LCI) Announces Earnings Results  2021/02/04 19:53:01 Transcript Daily
Lannett (NYSE:LCI) released its quarterly earnings results on Wednesday. The company reported $0.08 earnings per share for the quarter, hitting the consensus estimate of $0.08, Briefing.com reports. The firm had revenue of $133.92 million for the quarter, compared to analysts’ expectations of $130.00 million. Lannett had a negative net margin of 5.09% and a positive […]
   Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations  2021/02/03 21:15:00 PR Newswire
PHILADELPHIA, Feb. 3, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 second quarter ended December 31, 2020. "For the fiscal 2021 second quarter, net sales exceeded our expectations, and adjusted earnings per share and adjusted…
   Preview: Lannett's Earnings  2021/02/02 10:17:00 Benzinga
On Wednesday, February 03, Lannett (NYSE:LCI) will release its latest earnings report. Here is Benzinga's outlook for the company. What Are Earnings, …
   Alembic Pharma receives USFDA approval for Metolazone tablets  2020/12/03 07:15:23 Economic Times India
New Delhi: Drug firm Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Metolazone tablets, indicated for the treatment of salt and water retention caused by heart failure or kidney disease. The approved product is therapeutically equivalent to the reference listed drug product Zaroxolyn Tablets 2.5 mg, 5 mg and 10 mg of Lannett Company, Inc. In a regulatory filing, Alembic Pharmaceuticals said "it has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Metolazone tablets USP 2.5 mg, 5 mg, and 10 mg". Metolazone tablets are indicated for the treatment of salt and water retention including edema accompanying congestive heart failure, edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
   Lippert Components Subsidiary Completes Acquisition of Challenger Door - Stocks News Feed  2020/11/20 21:15:00 Stocks News Feed
ELKHART, Ind.–(BUSINESS WIRE)–LCI Industries (NYSE: LCII) today announced that its wholly-owned subsidiary, Lippert Components, Inc. (“LCI”), a supplier of a broad array of highly engineered components for the leading original equipment manufacturers (“OEMs”) in the recreation and transportation product markets, and the related aftermarkets of those industries, has acquired substantially all of the business assets… Read More »Lippert Components Subsidiary Completes Acquisition of Challenger Door
   Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance  2020/11/04 21:15:00 PR Newswire
PHILADELPHIA, Nov. 4, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a solid achievement, given our current competitive…
   $0.11 EPS Expected for Lannett Company, Inc. (NYSE:LCI) This Quarter  2020/10/20 17:52:52 Transcript Daily
Wall Street analysts predict that Lannett Company, Inc. (NYSE:LCI) will announce $0.11 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Lannett’s earnings. The highest EPS estimate is $0.12 and the lowest is $0.10. Lannett posted earnings of $0.22 per share during the same quarter last year, which […]
   $129.89 Million in Sales Expected for Lannett Company, Inc. (NYSE:LCI) This Quarter  2020/10/20 16:12:48 Transcript Daily
Equities research analysts expect Lannett Company, Inc. (NYSE:LCI) to report sales of $129.89 million for the current quarter, according to Zacks. Three analysts have issued estimates for Lannett’s earnings, with estimates ranging from $125.00 million to $132.58 million. Lannett reported sales of $127.34 million during the same quarter last year, which would suggest a positive […]
   Lippert Components Subsidiary Completes Acquisition of Challenger Door - Stocks News Feed  2020/11/20 21:15:00 Stocks News Feed
ELKHART, Ind.–(BUSINESS WIRE)–LCI Industries (NYSE: LCII) today announced that its wholly-owned subsidiary, Lippert Components, Inc. (“LCI”), a supplier of a broad array of highly engineered components for the leading original equipment manufacturers (“OEMs”) in the recreation and transportation product markets, and the related aftermarkets of those industries, has acquired substantially all of the business assets… Read More »Lippert Components Subsidiary Completes Acquisition of Challenger Door
   Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance  2020/11/04 21:15:00 PR Newswire
PHILADELPHIA, Nov. 4, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a solid achievement, given our current competitive…
   $0.11 EPS Expected for Lannett Company, Inc. (NYSE:LCI) This Quarter  2020/10/20 17:52:52 Transcript Daily
Wall Street analysts predict that Lannett Company, Inc. (NYSE:LCI) will announce $0.11 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Lannett’s earnings. The highest EPS estimate is $0.12 and the lowest is $0.10. Lannett posted earnings of $0.22 per share during the same quarter last year, which […]
   $129.89 Million in Sales Expected for Lannett Company, Inc. (NYSE:LCI) This Quarter  2020/10/20 16:12:48 Transcript Daily
Equities research analysts expect Lannett Company, Inc. (NYSE:LCI) to report sales of $129.89 million for the current quarter, according to Zacks. Three analysts have issued estimates for Lannett’s earnings, with estimates ranging from $125.00 million to $132.58 million. Lannett reported sales of $127.34 million during the same quarter last year, which would suggest a positive […]
   Drugs of Ursodeoxycholic Acid Market Emerging Trends and Worldwide Growth Factor by 2020-2025 | Dr. Falk, Daewoong, Teva, Epic, Mitsubishi, Lannett, Mylan, Bruschettini, Impax, Shanghai, Grindeks  2020/10/12 12:38:30 OpenPR
The growing demand for Drugs of Ursodeoxycholic Acid has provided a major boost to the Global Drugs of Ursodeoxycholic Acid Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at

 関連キーワード  (医薬品 米国株 LANNETT COMPANY LCI )

 twitter  (公式ツイッターやCEOツイッターなど)